His primary areas of study are Molecular biology, Cancer research, DNA damage, Cancer and DNA repair. He combines subjects such as Cell culture, Mutation, Downregulation and upregulation, Gelatinase and Cell biology with his study of Molecular biology. His studies deal with areas such as Transgene, HDAC11, Histone deacetylase 2, HDAC4 and Tumor suppressor gene as well as Cancer research.
The study incorporates disciplines such as Carcinogenesis, Cell cycle, Kinase and DNA replication in addition to DNA damage. His Cancer research incorporates themes from Extracellular matrix, Cell type and Stromal cell, Pathology. His DNA repair research incorporates elements of CHEK1, Cytotoxic T cell, G2-M DNA damage checkpoint and NAD+ kinase.
Maxwell Sehested focuses on Topoisomerase, Biochemistry, Pharmacology, Molecular biology and Cancer research. He has included themes like Etoposide, Clonogenic assay and Mechanism of action in his Topoisomerase study. The concepts of his Pharmacology study are interwoven with issues in Daunorubicin, Chemotherapy, Dexrazoxane, Anthracycline and In vivo.
In his study, Gene expression is strongly linked to Cell culture, which falls under the umbrella field of Molecular biology. His Cancer research research is multidisciplinary, incorporating elements of Cancer, Pathology and Histone deacetylase, Histone deacetylase 2, Belinostat. His work deals with themes such as Carcinogenesis and DNA replication, which intersect with DNA damage.
His primary scientific interests are in Cancer research, In vivo, Pharmacology, Belinostat and Nicotinamide phosphoribosyltransferase. His study in Cancer research is interdisciplinary in nature, drawing from both Acetylation, Immunology and Histone deacetylase, Histone, Histone deacetylase 2. His Pharmacology research includes themes of In vitro and Dexrazoxane, Anthracycline.
His Belinostat study combines topics in areas such as Histone deacetylase inhibitor and Molecular biology. His research integrates issues of Cancer cell, Cancer, Cell culture and Nicotinic agonist in his study of Nicotinamide phosphoribosyltransferase. His research investigates the connection between Nicotinamide adenine dinucleotide and topics such as DNA repair that intersect with issues in DNA damage.
His scientific interests lie mostly in Cancer research, Nicotinamide phosphoribosyltransferase, Cell culture, Pharmacology and Molecular biology. His work carried out in the field of Cancer research brings together such families of science as Histone deacetylase, Histone deacetylase 2 and Immunology, Lymphoma. His study looks at the relationship between Nicotinamide phosphoribosyltransferase and fields such as Cancer cell, as well as how they intersect with chemical problems.
His study in Cell culture is interdisciplinary in nature, drawing from both Blot, Gelatinase, Nicotinic agonist, Cytotoxicity and Antibody. His Pharmacology research includes elements of In vitro, Topoisomerase and Dexrazoxane, Anthracycline. The various areas that Maxwell Sehested examines in his Molecular biology study include Collagenase, Gelatinase A, Granulocyte and Polyclonal antibodies.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Jirina Bartkova;Zuzana Ho rcaron;ejší;Karen Koed.
Nature (2005)
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Jirina Bartkova;Nousin Rezaei;Michalis Liontos;Panagiotis Karakaidos.
Nature (2006)
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Nagma Khan;Michael Jeffers;Sampath Kumar;Craig Hackett.
Biochemical Journal (2008)
Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage.
Randi G. Syljuåsen;Claus Storgaard Sørensen;Lasse Tengbjerg Hansen;Kasper Fugger.
Molecular and Cellular Biology (2005)
53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer
Richard A. DiTullio;Richard A. DiTullio;Tamara A. Mochan;Tamara A. Mochan;Monica Venere;Monica Venere;Jirina Bartkova.
Nature Cell Biology (2002)
Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases.
B S Nielsen;N Borregaard;J R Bundgaard;S Timshel.
Gut (1996)
Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha.
Jack B Cowland;Ole E Sørensen;Maxwell Sehested;Niels Borregaard.
Journal of Immunology (2003)
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage
Jirina Bartkova;Nousin Rezaei;Michalis Liontos;Panagiotis Karakaidos.
(2006)
Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase is a marker of terminal neutrophil differentiation
N Borregaard;M Sehested;BS Nielsen;H Sengelov.
Blood (1995)
92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer.
Boye S. Nielsen;Susanne Timshel;Lars Kjeldsen;Maxwell Sehested.
International Journal of Cancer (1996)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Illinois at Urbana-Champaign
University of Copenhagen
University of Copenhagen
Copenhagen University Hospital
University of Copenhagen
Karolinska Institute
University of Geneva
Karolinska Institute
National Institutes of Health
Aarhus University Hospital
University of Melbourne
Boston University
Nanyang Technological University
University of California, Davis
University of Colorado Boulder
King Saud University
Max Delbrück Center for Molecular Medicine
Moderna Therapeutics (United States)
East China Normal University
Drexel University
Langley Research Center
Inserm : Institut national de la santé et de la recherche médicale
Newcastle University
Copenhagen University Hospital
University of Zurich
Instituto de Salud Carlos III